Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Future Pharmacology
Special Issues
Novel Therapeutic Approach to Inflammation and Pain
share announcement

Novel Therapeutic Approach to Inflammation and Pain

A special issue of Future Pharmacology (ISSN 2673-9879).

Deadline for manuscript submissions: closed (31 January 2025) | Viewed by 2440

Special Issue Editors

Dr. Roberto Mattioli

E-Mail Website
Guest Editor
Department of Biochemical Sciences, Sapienza University of Rome, Piazzale Aldo Moro 5, 00185 Rome, Italy
Interests: polyphenols; natural products; NaDES; inflammation; oxidative stress
Special Issues, Collections and Topics in MDPI journals
Dr. Alessia Mariano

E-Mail Website
Guest Editor
1. Department of Physiology and Pharmacology, Sapienza University of Rome, Piazzale Aldo Moro 5, 00185 Rome, Italy
2. Department of Biochemical Sciences, Sapienza University of Rome, Piazzale Aldo Moro 5, 00185 Rome, Italy
Interests: inflammation; pain; natural compounds; osteoarthritis; cellular pathways
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Inflammation and pain are two closely related issues that are often intricately linked in certain pathologies and are therefore frequently studied together in scientific research. It has been determined that they are interconnected by a complex signaling network based on a variety of molecules, receptors, and cellular pathways, which play fundamental roles in the onset and development of pathological conditions such as, for example, cancer, osteoarthritis, metabolic disorders, and autoimmune disease. However, although many advances have been made in this research field, the whole mechanisms responsible for inflammatory and painful signaling have not been fully clarified. Moreover, from a therapeutical perspective, currently available analgesic and anti-inflammatory drugs are often characterized by various side effects that limit their clinical administration. In this context, understanding these mechanisms and identifying new therapeutic targets would pave the way for new discoveries in the pharmaceutical field to provide innovative alternatives to inflammation and pain treatment. At the same time, it is important to discover and develop new molecules with increasingly minimal side effects.

In this Special Issue of Pharmaceutics, we invite authors to submit original research articles or reviews in the fields of pain and inflammation. Research areas may include (but are not limited to) the following topics:

  • Study of alternative targets or novel therapeutic strategies;
  • New pharmaceutical formulations;
  • Drug delivery systems as well as drug repositioning approaches.

Hoping for your active participation, we look forward to receiving your contributions.

You may choose our Joint Special Issue in Pharmaceutics.

Dr. Roberto Mattioli
Dr. Alessia Mariano
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Future Pharmacology is an international peer-reviewed open access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • inflammation
  • pain
  • chronical disease
  • drug repositioning
  • intracellular pathways
  • drug delivery systems
  • novel therapeutic strategies

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Other

11 pages, 1358 KiB  
Communication
Anti-Inflammatory Potential of Umckalin Through the Inhibition of iNOS, COX-2, Pro-Inflammatory Cytokines, and MAPK Signaling in LPS-Stimulated RAW 264.7 Cells
by So-Yeon Oh and Chang-Gu Hyun
Future Pharmacol. 2025, 5(1), 6; https://doi.org/10.3390/futurepharmacol5010006 - 21 Jan 2025
Viewed by 605
Abstract
Background/Objectives: Umckalin, a coumarin derivative abundantly present in the root extract of Pelargonium sidoides, is a key bioactive compound known for its antimicrobial, antiviral, antitubercular, and immunomodulatory properties. Its therapeutic potential has been extensively studied, particularly in the context of respiratory diseases. [...] Read more.
Background/Objectives: Umckalin, a coumarin derivative abundantly present in the root extract of Pelargonium sidoides, is a key bioactive compound known for its antimicrobial, antiviral, antitubercular, and immunomodulatory properties. Its therapeutic potential has been extensively studied, particularly in the context of respiratory diseases. This study aimed to evaluate the potential of umckalin as a therapeutic agent for chronic inflammatory diseases and to elucidate its underlying mechanisms of action. Methods: Using lipopolysaccharide (LPS)-stimulated RAW 264.7 macrophages as an experimental model, we investigated the inhibitory effects of umckalin on inflammatory mediators and cytokine production. We measured levels of nitric oxide (NO), prostaglandin E2 (PGE2), tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), and interleukin-1 beta (IL-1β), and assessed the expression of inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2). Additionally, the regulation of MAPK signaling pathways, including JNK, p38 MAPK, and ERK, was analyzed. Results: The results demonstrated that umckalin significantly reduced the levels of NO, PGE2, TNF-α, IL-6, and IL-1β in LPS-stimulated RAW 264.7 cells. Umckalin also suppressed the expression of iNOS and COX-2, leading to decreased NO and PGE2 production. Furthermore, umckalin effectively regulated inflammatory responses by reducing the phosphorylation of MAPK signaling pathways, including JNK, p38 MAPK, and ERK. Conclusions: These findings indicate that umckalin inhibits the production of TNF-α, IL-6, IL-1β, and NO, while regulating MAPK signaling pathways, thereby suppressing the expression of iNOS and COX-2. This study highlights the potent anti-inflammatory effects of umckalin and suggests its potential as a promising candidate for the treatment of chronic inflammatory diseases. Full article
(This article belongs to the Special Issue Novel Therapeutic Approach to Inflammation and Pain)
►▼ Show Figures

Figure 1

Other

Jump to: Research

22 pages, 636 KiB  
Systematic Review
Antinociceptive Potential of Croton Genus: A Systematic Review
by José Antonio Guerrero-Solano, Thania Alejandra Urrutia-Hernández, Tania Flores-Bazán, Karina Isabel Casco-Gallardo, Beatriz del Carmen Coutiño-Laguna, Nereida Violeta Vega-Cabrera and Osmar Antonio Jaramillo-Morales
Future Pharmacol. 2024, 4(4), 853-872; https://doi.org/10.3390/futurepharmacol4040045 - 30 Nov 2024
Viewed by 638
Abstract
The genus Croton (Euphorbiaceae) encompasses numerous species recognized for their diverse medicinal applications, particularly in pain management. This systematic review aims to compile and analyze the scientific evidence on the antinociceptive properties of Croton species. The review protocol was registered in [...] Read more.
The genus Croton (Euphorbiaceae) encompasses numerous species recognized for their diverse medicinal applications, particularly in pain management. This systematic review aims to compile and analyze the scientific evidence on the antinociceptive properties of Croton species. The review protocol was registered in the Open Science Framework (OSF) associated project: osf.io/z4juf. Using the PRISMA methodology, an exhaustive search was conducted in databases such as PubMed, Scopus, and Web of Science to identify relevant studies published to date. The review includes preclinical studies in animal models that investigate the mechanisms of action and efficacy of Croton extracts and isolated compounds in pain inhibition. The results indicate that 28 Croton species exhibit significant antinociceptive effects, attributed to bioactive compounds such as diterpenes, alkaloids, and flavonoids. These compounds interact with multiple biological pathways, including ion channels, such as TRPV1, K/ATP, and ASIC channels, as well as the inhibition of the synthesis of inflammatory mediators, particularly prostaglandins. This review highlights the potential of Croton as a source of novel analgesic agents and emphasizes the necessity for further clinical studies. Additionally, integrating ethnobotanical and pharmacological knowledge is suggested to develop innovative and effective treatments for pain management. Full article
(This article belongs to the Special Issue Novel Therapeutic Approach to Inflammation and Pain)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop